Could carbamazepine-acetazolamide interaction lead to a severe hepatocellular liver injury? an interaction that needs to be uncovered

Eur J Clin Pharmacol. 2023 Jun;79(6):873-874. doi: 10.1007/s00228-023-03497-1. Epub 2023 Apr 18.

Authors

Khadija Mansour¹, Raoudha Slim², Malek Sassi³, Nesrine Ben-Sayed⁴, Neila Fathallah², Bouraoui Ouni²

Affiliations

¹ Department of Pharmacology, Fattouma Bourguiba University Hospital, Monastir, Tunisia. khadija.mansour2@gmail.com.
² Laboratoire de Biophysique Métabolique Et Pharmacologie Appliquée (LR 12ES02), Faculté de Médecine de Sousse, Université de Sousse, Sousse, Tunisia.
³ Faculty of Pharmacy of Monastir, Monastir, Tunisia.
⁴ Department of Clinical Hematology, Farhat Hached Hospital, Sousse, Tunisia.

PMID: 37072528
DOI: 10.1007/s00228-023-03497-1

No abstract available

Keywords: acetazolamide; carbamazepine; drug-drug interaction; liver injury; protein plasma binding.

Publication types

Letter

MeSH terms

Acetazolamide
Benzodiazepines
Carbamazepine / adverse effects
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*

Substances

Acetazolamide
Carbamazepine
Benzodiazepines